Empliciti Market Report 2026

Empliciti Market Overview

• The Empliciti market growth in the historic period has been driven by increasing multiple myeloma incidence, limited efficacy of traditional chemotherapy • Market expansion is supported by growing adoption of immunotherapy protocols, expanding pipeline of monoclonal antibodies • Growth Driver: Rising Prevalence Of Multiple Myeloma Fuels Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Empliciti Market?

Empliciti (elotuzumab) is a prescription medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is classified as a monoclonal antibody and works by targeting and enhancing the immune system’s ability to fight cancer cells. The main types of indication for empliciti are active multiple myeloma and smoldering multiple myeloma. Active myeloma is a progressing blood cancer marked by CRAB criteria, which damages bones, red blood cells, kidneys, or myeloma-defining events from predictive markers or imaging. It is classified into various drug classes, such as monoclonal antibodies, immunomodulatory agents, and proteasome inhibitors. It is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and used by various end users, such as hospitals, clinics, ambulatory care, and home care.

What Is The Empliciti Market Growth Forecast?

The growth in the forecast period can be attributed to growing adoption of immunotherapy protocols, expanding pipeline of monoclonal antibodies, increasing survival rates driving long term treatment demand, favorable reimbursement for oncology biologics, advancements in immune based drug development. Major trends in the forecast period include combination monoclonal antibody therapies, immune system targeted cancer treatments, shift toward personalized multiple myeloma care, rising use of immunotherapy in oncology, growing adoption of long term biologic regimens.

Global Empliciti Market Segmentation

1) By Indication: Active Multiple Myeloma, Smoldering Multiple Myeloma 2) By Drug Class: Monoclonal Antibodies, Immunomodulatory Agents, Proteasome Inhibitors 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Empliciti Market?

The increasing prevalence of multiple myeloma is expected to propel the growth of the empliciti market going forward. Multiple myeloma is a cancer of the plasma cells, a type of white blood cell found in bone marrow, which leads to abnormal cell growth and can cause damage to bones, kidneys, and the immune system. The prevalence of multiple myeloma is driven by factors such as an aging population and improved diagnostic techniques. Empliciti targets the SLAMF7 protein on myeloma and natural killer (NK) cells, boosting the immune system's ability to detect and eliminate cancer cells. It enhances NK cell activity and promotes antibody-dependent cellular cytotoxicity (ADCC), helping to slow disease progression when combined with other treatments. For instance, in August 2024, the American Cancer Society, a US-based non-profit organization, in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 in women. Additionally, around 12,540 deaths are anticipated, including 7,020 in men and 5,520 in women. Therefore, the increasing prevalence of multiple myeloma will drive the growth of the empliciti industry. The rising demand for targeted cancer therapies is significantly driving the growth of the empliciti market in the future. Targeted cancer therapies focus on attacking cancer cells by identifying specific molecular markers, reducing harm to healthy cells. The demand for targeted cancer therapies is rising due to advancements in precision medicine, increasing cancer prevalence, improved treatment efficacy, and a growing focus on minimizing side effects. Empliciti targets SLAMF7, a protein on multiple myeloma and immune cells, boosting the immune system to attack cancer. This dual approach enhances precision while sparing healthy tissues. For instance, in June 2024, according to the Royal College of Radiologists, a UK-based professional body responsible for the specialties of clinical oncology and clinical radiology, in 2023, the demand for systemic anti-cancer therapies (SACT), encompassing chemotherapy, experienced a growth of 6-8%. Therefore, rising demand for targeted cancer therapies will drive the growth of the empliciti industry. The rising healthcare expenditure is set to propel the growth of the empliciti market moving forward. Healthcare expenditure is the total amount spent on healthcare services, including medical treatments, equipment, infrastructure, and personnel. Healthcare expenditure is driven by factors such as an aging population, increased prevalence of chronic diseases, advancements in medical technology, and the growing demand for better. Rising healthcare expenditure boosts investment in advanced cancer therapies like Empliciti, facilitating broader access to innovative treatments. This funding enhances healthcare infrastructure and supports research, leading to improved outcomes in cancer care. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, rising healthcare expenditure will drive the growth of the empliciti industry.

Key Players In The Global Empliciti Market

Major companies operating in the empliciti market are Bristol-Myers Squibb Company

Regional Insights

North America was the largest region in the empliciti market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Empliciti Market?

The empliciti market consists of sales of combination therapies, and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Empliciti Market Report 2026?

The empliciti market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the empliciti industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.